Neurorx and relief therapeutics announce data monitoring committee determination to continue phase 2/3 trial of rlf-100 for critical covid-19

The data monitoring committee gave a positive opinion to continue the study of rlf-100 in patients with critical covid-19 with respiratory failure.

EKSO Ratings Summary

EKSO Quant Ranking